Verifying that a somatic variant does not exist in a heterogeneic tissue with low tumour cellularity poses the problem; what depth of coverage is needed to confirm a true negative result? The potential negative impact to patient and family members if they receive a false negative result for targeted NGS may be significant.
← all excerpts
Next-generation sequencing in clinical oncology: next steps towards clinical validation.
1
—
—